Objective: To identify factors that increase the risk of developing febrile neutropenia (FN) during the first cycle of chemotherapy in breast cancer patients.
Methods: In this retrospective study, we reviewed the records of 211 patients with confirmed breast cancer treated with chemotherapy at the Princess Norah Oncology Center, King Abdulaziz Medical City, Jeddah, Kingdom of Saudi Arabia between January 2010 and May 2012. Statistical analysis was conducted using descriptive analysis, univariate, and multivariate logistic regressions. A multivariate regression of FN occurrence in the first cycle was developed.
Results: The median age of patients was 48 years. Febrile neutropenia was documented in 43 (20.3%) of 211 patients. Twenty-one (49%) of the 43 patients had FN during the first cycle of chemotherapy. A multivariate logistic regression revealed that age (odds ratio [OR] 1.059, 95% confidence interval [CI]: 1.007-1.114), non-anthracycline and/or taxane-based chemotherapy regimens (OR of 39.488; 95% CI: 4.995-312.187), and neo-adjuvant chemotherapy (OR of 8.282; 95% CI: 1.667-41.152) were the most important independent risk factors of FN.
Conclusion: Identifying risk factors of FN may help to target high-risk patients with granulocyte colony-stimulating factor prophylaxis and reduce FN incidences, with subsequent morbidities and mortalities.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Introduction: Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) therapy is indicated as first-line or neoadjuvant chemotherapy (NAC) for patients with advanced or metastatic urothelial carcinoma (UC). However, no studies reported ddMVAC therapy with pegfilgrastim (3.6 mg) in Japanese patients.
View Article and Find Full Text PDFEvaluation of efficacy of GCSF in reducing neutropenia among carcinoma patients undergoing anti-cancer chemotherapy. A prospective cohort study.
PLoS One
January 2025
Department of Pharmacy, Kohat University of Science and Technology (KUST), Kohat, Pakistan.
The use of granulocyte colony-stimulating factor (GCSF) to control febrile neutropenia (FN) caused by anti-cancer chemotherapy is well documented but it still needs to evaluated with respect to the specific type of cancer and chemotherapeutic agents. The present study evaluates the efficacy of adjunctive GCSF for treating FN after taking anticancer therapy by measuring clinical, hematological and microbiological outcomes. It is a single center study conducted at Hayatabad Medical Complex (HMC), Peshawar, Pakistan.
View Article and Find Full Text PDFContribution of paranasal sinus, chest, and abdomen/pelvis computed tomography in patients with febrile neutropenia.
PLoS One
January 2025
Department of Radiology, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France and Université Paris Cité, Paris, France.
Objective: Febrile neutropenia (FN) is a serious clinical event, associated with significant morbidity and mortality. Imaging has a central role in the identification of the fever cause. The study objectives were to assess abnormalities of potential infectious origin on paranasal sinus, chest and abdomen/pelvis CT scans performed during an episode of FN, in patients with or without specific clinical signs, and to evaluate their impact on the frequency of changes in treatment.
View Article and Find Full Text PDFIncidental neutropenia: An emergency medicine focused approach.
Am J Emerg Med
December 2024
The University of Texas Southwestern Medical Center, Department of Emergency Medicine, 5323 Harry Hines Boulevard, Dallas, TX 75390, United States.
Introduction: Neutropenia is defined as an absolute neutrophil count (ANC) < 1500 cells/microL and may be discovered incidentally in an asymptomatic, afebrile patient.
Objective: This narrative review provides an approach to the afebrile emergency department patient with incidental neutropenia.
Discussion: Neutropenia is an ANC < 1500 cells/microL, with mild neutropenia defined as an ANC ≥ 1000 to <1500 cells/microL, moderate ≥500 to <1000 cells/microL, severe <500 cells/microL, and agranulocytosis <200 cells/microL.
Genetic Polymorphisms of DNA Repair Genes and their Influence on Paclitaxel based Chemotherapy Induced Toxicity Reactions in Breast Cancer Patients.
Asian Pac J Cancer Prev
December 2024
Department of Oncology, Krishna Vishwa Vidyapeeth "Deemed to be University", Taluka-Karad, Dist- Satara, Pin-415 539, (Maharashtra) India.
Background: Systemic chemotherapy constitutes an indispensable component of breast cancer (BC) management, where therapeutic drug combinations such as anthracyclines, platinum compounds, and taxanes form the cornerstone of standard treatment protocols. Although DNA repair genes are pivotal in cancer susceptibility, their specific roles in mediating acute or chronic toxicity outcomes induced by chemotherapy remain undetermined. Consequently, this study was planned to elucidate the impact of polymorphisms in base excision repair (BER) genes, including XRCC1, XRCC2, XRCC3, APE1, and hOGG1, on treatment response and toxicity outcomes in BC patients undergoing paclitaxel and doxorubicin-based chemotherapy within an Indian population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!